



JFW

INFORMATION DISCLOSURE STATEMENT

Applicant : Otsuki, et al.
App. No : 10/785,446
Filed : February 23, 2004
For : METHOD OF TREATMENT OF
DISEASE USING AN ADENOSINE A1
RECEPTOR ANTAGONIST
Examiner : Royds, L. E.
Art Unit : 1614

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

10-19-06

(Date)

Ned A. Israelsen, Reg. No. 29,655

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 14 references to be considered by the Examiner. Also enclosed are 7 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 10-19-06

By:

Ned A. Israelsen
Registration No. 29,655
Attorney of Record
Customer No. 20,995
(619) 235-8550

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(Multiple sheets used when necessary)*

SHEET 1 OF 1

Application No.	10/785446
Filing Date	02-23-2004
First Named Inventor	Otsuki, et al.
Art Unit	1614
Examiner	Royds, Leslie E.
Attorney Docket No.	NOCAR.007A

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	5,736,528	04/07/1998	Belardinelli et al.	
	2	6,254,889	07/03/2001	Kigoshi, et al.	
	3	2002/0136775	09/26/2002	Thosar, et al.	
	4	2005/0004145	01/06/2005	Widder, et al.	
	5	2005/0239759	10/27/2002	Otsuki, et al.	
	6	2006/0030572	02/09/2006	Widder, et al.	
	7	2006/0035911	02/16/2006	Widder, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	8	EP 0 619 316	10-12-1994	Shimada, et al.		
	9	EP 0 970 696	01-12-2000	Hropot, Max		
	10	WO 04/096228	11/11/2004	Widder, et al.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	11	Dittrich, et al., "Effects of the Adenosine A1 Receptor Antagonist, KW-3902, Late Breaking Trials, Heart Failure, Helsinki, Finland, June 17-20, 2006	
	12	FINGL, et al. " The Pharmacological Basis of Therapeutics" Ch. 1, p. 1 (1975)	
	13	Givertz, et al. "Effect of the Adenosine A1 Receptor Antagonist, KW-3902," Late Breaking Trials, Heart Failure 2006, Helsinki, Finland, June 17-21, 2006	
	14	Remington's Pharmaceutical Sciences, Mack Publishing Company, 18th Edition, 1990	

3006719
101106

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.